Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:BTMD NASDAQ:CRBU NASDAQ:IPSC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$7.04+0.6%$7.43$5.47▼$11.99$146.28MN/A69,650 shs24,637 shsBTMDbiote$3.39-1.7%$3.62$2.76▼$6.98$167.60M1.19171,468 shs75,218 shsCRBUCaribou Biosciences$1.80-1.6%$1.91$0.66▼$3.00$167.62M2.541.27 million shs1.06 million shsIPSCCentury Therapeutics$0.49-1.5%$0.55$0.34▼$1.86$42.31M1.78710,774 shs266,860 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+4.95%-11.84%-13.79%-9.91%-12.61%BTMDbiote+2.37%0.00%+18.15%-12.21%-41.13%CRBUCaribou Biosciences+1.67%+1.10%-7.58%+57.76%-13.68%IPSCCentury Therapeutics-0.72%-2.57%-11.50%-15.90%-68.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$7.04+0.6%$7.43$5.47▼$11.99$146.28MN/A69,650 shs24,637 shsBTMDbiote$3.39-1.7%$3.62$2.76▼$6.98$167.60M1.19171,468 shs75,218 shsCRBUCaribou Biosciences$1.80-1.6%$1.91$0.66▼$3.00$167.62M2.541.27 million shs1.06 million shsIPSCCentury Therapeutics$0.49-1.5%$0.55$0.34▼$1.86$42.31M1.78710,774 shs266,860 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+4.95%-11.84%-13.79%-9.91%-12.61%BTMDbiote+2.37%0.00%+18.15%-12.21%-41.13%CRBUCaribou Biosciences+1.67%+1.10%-7.58%+57.76%-13.68%IPSCCentury Therapeutics-0.72%-2.57%-11.50%-15.90%-68.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.33190.06% UpsideBTMDbiote 2.50Moderate Buy$6.0075.95% UpsideCRBUCaribou Biosciences 3.00Buy$6.67263.31% UpsideIPSCCentury Therapeutics 3.00Buy$3.75666.87% UpsideCurrent Analyst Ratings BreakdownLatest IPSC, CRBU, BTMD, and ACTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025ACTUActuate TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.008/25/2025ACTUActuate TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.008/18/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/7/2025BTMDbioteB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$8.00 ➝ $4.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.01 per shareN/ABTMDbiote$197.19M0.85$0.78 per share4.40($2.78) per share-1.23CRBUCaribou Biosciences$9.99M17.10N/AN/A$2.79 per share0.66IPSCCentury Therapeutics$6.59M6.41N/AN/A$1.90 per share0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$27.28MN/A0.00∞N/AN/AN/A-281.83%N/ABTMDbiote$3.16M$0.903.796.31N/A15.73%-21.00%18.26%11/11/2025 (Estimated)CRBUCaribou Biosciences-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)IPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-11.53%-6.94%11/4/2025 (Estimated)Latest IPSC, CRBU, BTMD, and ACTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACTUActuate Therapeutics-$0.19-$0.30-$0.11-$0.30N/AN/A8/14/2025Q2 2025IPSCCentury Therapeutics-$0.38-$0.38N/A-$0.38$0.03 millionN/A8/12/2025Q2 2025CRBUCaribou Biosciences-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 million8/6/2025Q2 2025BTMDbiote$0.06$0.10+$0.04$0.10$49.52 million$48.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A0.730.73BTMDbioteN/A0.980.74CRBUCaribou BiosciencesN/A6.666.66IPSCCentury TherapeuticsN/A10.7210.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ABTMDbiote21.68%CRBUCaribou Biosciences77.51%IPSCCentury Therapeutics50.20%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%BTMDbiote24.00%CRBUCaribou Biosciences9.50%IPSCCentury Therapeutics5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1020.78 million6.37 millionN/ABTMDbiote19449.44 million37.57 millionNot OptionableCRBUCaribou Biosciences10093.12 million84.28 millionOptionableIPSCCentury Therapeutics17086.39 million82.07 millionOptionableIPSC, CRBU, BTMD, and ACTU HeadlinesRecent News About These CompaniesCentury Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street ZenSeptember 8, 2025 | americanbankingnews.comCentury Therapeutics to Present at Global Investment ConferenceAugust 23, 2025 | msn.comCentury Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceAugust 22, 2025 | globenewswire.comCentury Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 15, 2025 | finanznachrichten.deCentury Reports Flat Loss in Fiscal Q2August 15, 2025 | theglobeandmail.comCentury Therapeutics Reports Q2 2025 Financials and UpdatesAugust 14, 2025 | tipranks.comCentury Therapeutics Reports Q2 Results and Leadership ChangeAugust 14, 2025 | msn.comCentury Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comAll You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong BuyJuly 21, 2025 | zacks.comCentury Therapeutics Inc. Stock Grades | IPSC | Barron'sJuly 16, 2025 | barrons.comDespite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain StockJuly 15, 2025 | sharewise.comSDespite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain StockJuly 15, 2025 | zacks.comUniversity City biotech Century Therapeutics is cutting 72 jobs, about half its workforceJuly 11, 2025 | msn.comCentury Therapeutics to Cut 51% of WorkforceJuly 8, 2025 | marketwatch.comCentury Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum - NasdaqJune 27, 2025 | nasdaq.comCentury Therapeutics, Inc. (IPSC) - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comCentury Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced MomentumJune 25, 2025 | zacks.comIPSC Century Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comFast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a BargainJune 6, 2025 | zacks.comCentury Therapeutics to Present Preclinical Data at EULAR 2025 CongressMay 31, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSC, CRBU, BTMD, and ACTU Company DescriptionsActuate Therapeutics NASDAQ:ACTU$7.04 +0.04 (+0.57%) Closing price 04:00 PM EasternExtended Trading$7.02 -0.01 (-0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.biote NASDAQ:BTMD$3.39 -0.06 (-1.74%) Closing price 04:00 PM EasternExtended Trading$3.44 +0.05 (+1.45%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Caribou Biosciences NASDAQ:CRBU$1.80 -0.03 (-1.64%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.04 (+2.22%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Century Therapeutics NASDAQ:IPSC$0.49 -0.01 (-1.49%) Closing price 04:00 PM EasternExtended Trading$0.49 0.00 (-0.37%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
